Tag: Seogkyoung-Kong

Home / Seogkyoung-Kong

Categories

A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies

July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell...
seogkyoung-kong

We Are Online! Chat With Us!
Scan the code